Douglas Johnson

💡📛 𝐎𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐞𝐱𝐩𝐞𝐧𝐬𝐢𝐯𝐞 𝐦𝐢𝐬𝐭𝐚𝐤𝐞𝐬 𝐢𝐧 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐬𝐚𝐥𝐞𝐬? 𝐒𝐞𝐥𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭… 𝐛𝐮𝐭 𝐧𝐨𝐭 𝐭𝐡𝐞 𝐩𝐫𝐨𝐠𝐫𝐚𝐦. Joseph Hyland Authement (now VP of Sales at Mendaera) told me a story that every capital sales leader needs to hear. He walked into an account that had robotic systems collecting dust — millions in sunk capital, zero clinical utilization, and hospital leadership ready to pull the plug. Most reps would have walked away. Instead, Joseph did something different. He thought like a portfolio manager — not a salesperson. Over two years, he rebuilt the program from the ground up: ✔️ Re-engaged physicians ✔️ Rallied internal and hospital-side stakeholders ✔️ Built the clinical and strategic case ✔️ Made sure the system wasn’t just installed — it was adopted. And the result? The hospital went from “we’re done with robotics” to rolling out robots in 95+ facilities. Why? Because they didn’t just see a product anymore. They saw a scalable program that drove economic, clinical, and strategic ROI. 👉 This is the mindset shift capital reps need today. In medtech, your product isn't the pitch. The ecosystem, outcomes, and repeatability are the pitch. You’re not selling features — you’re selling transformation. That’s what separates elite capital leaders from everyone else. *Joseph and I finally met in person this weekend at AUA. This photo was at the end of the last day...where we were both exhausted from 3 days of life on the exhibit hall floor. 🎙️𝑪𝒉𝒆𝒄𝒌 𝒕𝒉𝒆 𝒄𝒐𝒎𝒎𝒆𝒏𝒕𝒔 𝒇𝒐𝒓 𝒍𝒊𝒏𝒌𝒔 𝒕𝒐 𝑱𝒐𝒔𝒆𝒑𝒉'𝒔 𝒇𝒊𝒓𝒔𝒕 𝒂𝒑𝒑𝒆𝒓𝒂𝒏𝒄𝒆 𝒐𝒏 𝒕𝒉𝒆 𝒔𝒉𝒐𝒘 3 𝒚𝒆𝒂𝒓𝒔 𝒂𝒈𝒐 𝒐𝒏 𝒄𝒂𝒑𝒊𝒕𝒂𝒍 𝒔𝒂𝒍𝒆𝒔 #medtech #medicaldevices #medicaldevice #medicaldevicesales #medicalsales #digitalhealth

118

12 Comments

$4.1B isn’t just growth, it’s urgency. That’s the market leap tissue diagnostics is making by 2029. From $8.3B → $12.4B, in just 6 years. But here’s the bigger signal: Tissue diagnostics is no longer just about identifying disease. It’s about how early, how accurately, and how personally we can do it. As someone building at the intersection of medicine and technology, I’ve seen this shift firsthand. AI is not an add-on. Digital pathology is not a nice-to-have. They’re essentials. Because when diagnosis gets smarter, everything downstream gets better, from treatment decisions to patient survival. Here’s my belief: Innovation in diagnostics isn’t optional anymore. It’s the backbone of better care. Curious to hear from others building in this space — 👉 What’s one shift diagnostic leaders can’t afford to ignore over the next 3 years? #TissueDiagnostics #PrecisionMedicine #AIinHealthcare #HealthTech #CancerCare #DigitalPathology #SudhakarKancharla #MedicalInnovation #DiagnosticsLeadership https://lnkd.in/gkv-rgnV

201

7 Comments

🚨 Exciting News from Medaxis 🚨 We’re proud to announce a three-year contract award with Partners Cooperative, Inc. for our Microjet Wound Therapy (MWT) portfolio. Partners Cooperative is a strategic alliance of leading health systems across the Midwest, Texas and Southeast, committed to drive operational excellence and we’re honored to support their goals with a ground-breaking wound therapy solution. 💡 What makes Microjet Wound Therapy unique? Designed to optimize the wound bed for healing, Microjet is a single device that: ✅ Cleans ✅ Debrides ✅ Disinfects Appropriate for all care settings — OR to bedside, clinic to long-term care — Microjet offers precision and control, removing non-viable tissue while leaving healthy tissue intact. 📣 Recognized by the FDA with Breakthrough Device Designation, MWT is helping transform wound therapy. 🔗 Learn more about Microjet Wound Therapy and how it can support your clinical goals. https://lnkd.in/giKXq_g8 #WoundTherapy #WoundBedPrep #InnovationInHealthcare #MicrojetWoundTherapy #BreakthroughDevice #HealthcareInnovation #Medaxis

88

9 Comments

We are thrilled to share some major news from our valued partner, the Midwest Pediatric Device Consortium (MPDC)! They have announced several incredible opportunities for the pediatric Medtech community. Major Funding Announcement: $400,000 Pitch Competition MPDC is collaborating with the UCSF-Stanford Pediatric Device Accelerator for the Fall 2025 PDC Pitch Competition, offering up to $100,000 per project along with advising, prototyping support, and commercialization coaching. This is a fantastic opportunity for U.S.-based academics, businesses, or startup innovators with a promising pediatric device idea. Applications Open: June 20, 2025 Total Awards: $400,000 Learn More & Apply: https://mpdc.smapply.us/ Upcoming MPDC Events: MPDC Webinar: Economics & Reimbursement Topic: Making Sense of Pediatric Medtech Health Economics Date: June 18, 2025 | 12:00 PM - 1:00 PM Register Here: https://lnkd.in/e8Sirdzb MPDC Webinar: Funding Topic: Bridging Pediatric Funding Gap Legislative Strategies Date: July 8, 2025 | 4:00 PM - 5:00 PM Register Here: https://lnkd.in/eR86gbCp MPDC 2025 Showcase in Cleveland, OH Join MPDC and their partners Project MedTech and JumpStart Inc. for insightful panels on SaMD and a live pitch competition with over $100K in awards. Date: July 9, 2025 Register Here: https://lnkd.in/eUKeB5p4 Project Medtech is proud to support MPDC's work in accelerating pediatric MedTech innovation. Don't miss out on these events and funding opportunities! #medicaldevices #startup #medtech #projectmedtech #innovation #medicaldevice #podcast #strategy

80

5 Comments

Wound Care at a Crossroads: Reclaiming Our Industry’s Narrative Wound care is a $30B+ global market — on par with global orthopedics. Yet the cost to patients and health systems is far, far greater. So why are we still struggling for credibility with investors? The answer: the skin substitute fallout and the perceptions we have allowed to exist around our industry. Over the last several years; fraud investigations, DOJ actions, and reimbursement uncertainty have cast a long shadow. The result? >$4.37B in measurable lost or delayed investment across the public and private markets, likely larger. In the latest Below the Knee newsletter, I broke down this story: How public company valuations collapsed, how investors pulled back from private deals, and what the forward-looking cost of missed innovation might be. This post kicks off a series where I’ll share those insights week by week. Because this isn’t just about policy — it’s about control. We need to take back our narrative. 👉 https://lnkd.in/eeAgS5aq #WoundCare #LimbSalvage #BelowTheKnee #HealthCareInvestment

50

4 Comments

Our entire team is still buzzing from last week's expanded FDA indication for SIR-Spheres® Y-90 resin microspheres, making it the first and only radioembolization therapy in the U.S. approved to treat both unresectable HCC and metastatic colorectal cancer (mCRC) of the liver! I've had countless conversations with staff and physicians about this milestone and am humbled by the support and positive feedback everyone has shared. At Sirtex Medical Limited, we don't just innovate for the sake of innovation. We innovate to solve real-life problems that physicians are facing so that they can provide the best patient care possible. That's exactly why we've built the SIR-Spheres® infrastructure to be flexible by enabling physicians to treat patients with the activity they need, when they need it. See how SIR-Spheres® stands out amongst other radioembolization therapies: https://lnkd.in/giM-PBPv

149

3 Comments

Avvio Medical Receives FDA Breakthrough Device Designation for Enhanced Lithotripsy System (ELS) We’re proud to share that the Avvio Enhanced Lithotripsy System (ELS) has received Breakthrough Device Designation from the FDA — recognizing its potential to advance the treatment of ureteral stones through microbubble‑enhanced acoustic cavitation lithotripsy. This technology is designed to simplify stone treatment by enabling care outside the operating room, supporting outpatient and ASC workflows, and expanding access for the Medicare‑aged population disproportionately affected by stone disease. It is designed to be used without routine general anesthesia and post-operative stents and our ongoing pivotal US IDE study has already validated patient tolerability of the procedure with oral anxiolytics and topical analgesic gel. We plan to submit a DeNovo for market clearance in early 2026 and a new dedicated category III CPT 0991T code will be effective in January. This milestone validates years of science, teamwork, and commitment to making stone treatment safer, simpler, and more accessible. #AvvioMedical #BreakthroughDevice #KidneyStones #Urology #Lithotripsy #MedicalDevices #Innovation #MinimallyInvasive #UreteralStones #Cavitation #ASC #MedicareAccess https://lnkd.in/gc2bRFsK

128

15 Comments

SynCardia Systems, LLC's parent company Picard Medical, Inc priced an IPO of $17 million on the NYSE. The funds are expected to support SynCardia’s Total Artificial Heart, helping it advance beyond its current FDA-approved 70cc Total Artificial Heart toward smaller 50cc. They will likely also give a strong R&D boost for the company’s next-gen Emperor Total Artificial Heart system, a fully implantable, pulsatile system that eliminates the need for an external pneumatic driver. Picard is also looking East, as it plans to support market expansion via a joint venture established in China. It will help them secure local presence in the market. 👏 These are very determined strategic moves from Picard Medical/ SynCardia’s CEO Patrick NJ Schnegelsberg. Looking forward to how they develop. 🔗 Get the full details: https://lnkd.in/edFQiBQN #MedicalDevices #MedicalEquipment #HealthTech #MedTechNews

57

1 Comment

With over 530 MedTech companies calling Minnesota home, this year’s MedTech MVP once again brought together 300+ innovators, investors, and collaborators to keep this dynamic industry pulsing with fresh ideas. From a powerful keynote by Mike Mahoney, CEO of Boston Scientific, to groundbreaking solutions tackling hypertension, critical limb ischemia, and the blood-brain barrier — the energy and insights shared were unstoppable, despite a tough funding climate. 💡 Emerging Highlights: ✅ CoraVie MEDICAL & Sonion: Revolutionizing continuous hypertension monitoring. ✅ Poseidon Medical: Bifurcated stents to restore flow below the knee. ✅ EnClear Therapies: Bypassing the blood-brain barrier to deliver therapies. ✅ Elucent Medical Inc. Medical: Precise, real-time tumor targeting for better outcomes. Despite uncertainty around tariffs and funding, the optimism is strong — with M&A activity picking up, the FDA embracing AI to boost efficiency, and panels agreeing that MedTech markets are heating up again. 👉 Watch the video to catch my key takeaways and see how these innovators are pushing the boundaries of what’s possible in MedTech. 🔗 Let’s keep the conversation going — what were your top highlights from this year’s MedTech MVP? Drop them below! #MedTech #Innovation #Healthcare #Startups #Leadership #Minnesota #MedTechMVP #BostonScientific Aimee Garza H. Richard Davis Anthony DePasqua Jim Fidacaro Jason Pesterfield

63

21 Comments

6:8 Medical Solutions and Sago Medica Announce Strategic Partnership to Distribute Life-Saving Hemorrhage Control Devices Across Italy Myrtle Beach, SC – 6:8 Medical Solutions, a veteran-owned small business specializing in innovative emergency medical technologies, is proud to announce a strategic partnership with Sago Medica, a leading distributor of advanced medical devices throughout Italy. This collaboration will bring the Popp Point Pressure™ family of hemorrhage control devices and products to emergency responders, hospitals, and military medical providers across the Italian healthcare system. Founded and led by Uriah Popp, a former U.S. Army Special Operations Medic, 6:8 Medical Solutions developed the Popp Point Pressure™ family of products to address the urgent need for rapid, effective control of compressible hemorrhage in both civilian and military environments. “This partnership with Sago Medica is an important step in our mission to place life-saving technology in the hands of those who need it most,” said Uriah Popp, CEO and inventor of the devices. “As a veteran and medic, I’ve seen firsthand how critical every second is when dealing with hemorrhage. Responding to trauma and providing life saving care can be stressful. Solutions must be rapidly available, intuitive to use, and simplify tasks. We design products and devices with these things in mind. It is imperative to change the outcome in those moments, .” The Popp Point Pressure™ family of products delivers focused pressure to bleeding sites, offering a novel approach to hemorrhage control in prehospital, austere, and battlefield conditions. Through this agreement, Sago Medica will distribute the full product line throughout Italy, supporting improved outcomes in trauma care. “We are honored to partner with 6:8 Medical Solutions and to introduce this revolutionary technology to the Italian market,” said Franco Fallavena, Managing Director of Sago Medica. “Uriah’s combat experience and insight have produced products that fills a vital gap in hemorrhage management as well as tourniquet conversion.” Headquartered in Myrtle Beach, South Carolina, 6:8 Medical Solutions continues to lead the way in veteran-led innovation for trauma care. For more information about the Popp Point Pressure™ Devices and distribution inquiries, visit www.68medical.com.

46

3 Comments

💸 MedTech Industry News – Week 28, 2025 💰 #Funding Restore Medical: raises $23m Series B for ContraBand HF device Plexāā | Creators of BLOOM⁴³: adds $4.5m to fund BLOOM43 U.S. launch Neuros Medical, Inc.: lands $56m Series D for Altius nerve-stimulation Adtec Healthcare Limited: secures $12m for next-gen cold-plasma device PIUR IMAGING GmbH: €5.6m growth round to scale 3-D ultrasound FluidAI Medical: $2m Canadian grant accelerates Stream & Origin Plasmacure: €6m Series A to advance cold-plasma wound therapy Amotio Health: raises €810k for revision-surgery tech Alva Health Inc.: wins $500k NSF grant for wearable stroke monitor Lucida Medical: £2.25m SBRI funds Pi prostate-MRI AI rollout Ebenbuild: €2.3m EIC grant to scale lung-twin platform The Blue Box Biomedical Solutions: Unconventional Ventures’ continued backing fuels development of its 88%-sensitivity urine-based breast-cancer test. 🏛 #Regulatory MatOrtho Ltd: ReCerf ceramic hip resurfacing gains CE mark Mendaera, Inc.: Focalist handheld robot wins 510k Exactech: Equinoxe scapula reconstruction wins 510k Hypervision Surgical: Hypersnap AI hyperspectral platform wins 510k Synchrony Medical: LibAirty airway-clearance system cleared by FDA Boston Scientific: Farapulse PFA label expanded by FDA Hilo by Aktiia: G0 cuff-less BP monitor is first OTC BP device cleared Morphic Medical: obesity device secures CE mark Caranx Medical: surgical-robot software cleared by FDA ArteraAI: prostate-cancer AI wins FDA Breakthrough status Abbott: TriClip TEER gains Medicare outpatient coverage 𝗗𝘆𝗺𝗶𝗰𝗿𝗼𝗻 Granted IDE Approval for Triadyme-C Artificial Disc 🧪 #ClinicalTrials CorWave: first human implant of wave-membrane LVAD completed Medtronic: first patient treated in Spyral Gemini hypertension pilot CorFlow: MOCA-II IDE pivotal trial approved by FDA PanTher Therapeutics chemo-patch enters human trial Miach Orthopaedics, Inc.: BEAR ACL implant shows positive data Radical Catheter Technologies: 8F guide catheter posts strong early results MediView XR, Inc. XR: 104-patient XR90 holographic-guidance study begins 🤝 #M&A Innovia Medical: buys Grace Medical & Hurricane Medical Alcon: to acquire LumiThera dry-AMD photobiomodulation device Companion Spine: to acquire Coflex, CoFix & Paradigm Spine assets Gilde Healthcare: merges Artinis & NIRx into global fNIRS leader 💡 #Innovation SoundHealth: Android app rolls out for SONU tinnitus band Highridge Medical: activL lumbar disc launches in U.S. InspireMD: CGuard Prime carotid stent debuts in U.S. 𝗦𝗦 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀: first robotic telesurgery for weight-loss case OraSure Technologies, Inc.: launches proteomics blood-collection device MMI - Medical Microinstruments, Inc.: first use of NanoWrist instruments & Synaptix platform Leaflet Solutions: launched by Sectoral to develop Scalarto catheter 📩 If you're building in #MedTech I am watching. DM us to share your update or milestone.

153

4 Comments

CODING UPDATE! U.S. Centers for Medicare & Medicaid Services (CMS) has issued a transitional pass-through payment billing code specifically for absorbable bone fixation screws and anchors.  The C1741 HCPCS code recognizes the patient benefit offered by innovative non-permanent implants, such as OSSIOfiber Compression Screws, by facilitating pass-through payments to hospitals and ASCs. Stay tuned for coding guide...  

216

6 Comments

What would you do if you were 32 years old and handed $150M in responsibility? That’s exactly the position Gary Thomas, the SVP of Manufacturing/Product Development at Onkos Surgical found himself in... leading multiple business units across MedTech with barely a decade of experience under his belt. No manual. No roadmap. Just grit, great people, and an insane amount of determination to not let it fall apart. In our recent episode of 𝐓𝐡𝐞 𝐌𝐞𝐝-𝐓𝐞𝐜𝐡 𝐓𝐚𝐥𝐞𝐧𝐭 𝐋𝐚𝐛 podcast, Gary shared how those early high-pressure years shaped the leader he is today and how the lessons from that time still serve him when product launches go sideways or when team members say, “this can’t be done.” Support. Vigilance. Determination. That’s how you lead when the stakes are high and the clock is ticking. Leadership isn’t about having all the answers. It's about having the backbone when others doubt, and the humility to lean on the people around you. If you're a MedTech leader navigating complex product launches and looking for real talk on what it actually takes to lead under pressure… this is an episode you won't want to miss! Thanks for being a valued guest on the show Gary! -MR 𝐏𝐒 Link to full episode and all the others in the comments. #podcast #medtechtalentlab #leadership #hiring #recruiting

79

11 Comments

Cordis recently unveiled new data from two significant peripheral studies showcasing its Selution SLR drug-eluting balloon. The company, headquartered in Miami Lakes, Florida, disclosed the 12-month outcomes from the SUCCESS PTA study at the esteemed Charing Cross Symposium in London. Additionally, it presented the SELUTION SFA Japan three-year findings at the Japan Endovascular Treatment Conference in Osaka. The findings from these studies, as per Cordis, validate the enduring effectiveness and safety of Selution SLR in addressing complex peripheral artery disease (PAD). Notably, the balloon demonstrated consistent efficacy and safety profiles across varied real-world patient cohorts, as highlighted in a recent news release. Cordis emphasized that the balloon's performance aligns favorably with top-tier benchmarks set by paclitaxel-eluting technologies.

44

1 Comment